Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

$23 $12

Earnings per common share - diluted:

Earnings per common share -

continuing operations $0.21 $0.12

Earnings per common share -

discontinued operations - (0.01)

Net earnings per common share -

diluted $0.21 $0.11

Weighted average shares - assuming

dilution 109 108

Stock-based compensation expense:

Cost of sales $3 $2

Selling, general and administrative 3 4

Research and development 1 1

Total stock-based compensation

expense $7 $7

$ in millions As of As of

March 31, December 31,

2008 2007

Cash & cash equivalents $484 $246

Marketable securities - current 21 288

Accounts receivable 462 497

Other receivables 88 86

Inventories 481 454

Marketable securities - long-term 52 17

Accounts payable & accrued

liabilities 423 443

Working capital 909 923

Total assets 4,886 4,762

Total debt 2,0
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
(Date:12/2/2009)The Scientist, a leading scientific magazine covering the life sciences, ranked Photometrics’ Evolve “Intelligent” EMCCD camera fourth among the publication’s “Top 10 Inn
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 2The Scientist Names Photometrics' Evolve EMCCD Camera One of the “Top 10 Innovations” of 2009 3
..., March 12 Micromet, Inc. (Nasdaq: MITI ), a bi...ary antibodies for the treatment of cancer, inflam...at it is regaining from its partner MedImmune the ...antibody candidate, blinatumomab, also known as MT...linical trial with blinatumomab for the treatment ...
... 12 Albert Liou, Corporate Vice President and Gen...national Corporation (Nasdaq: PRXL ), a leading ...resent "The True Value of Incorporating Asia into ...Medical Asia 2009 conference, to be held March 16 ...onvention & Exhibition Centre in Singapore. Mr...
...nds to acquire all outstanding shares of Genentech...nd early development to operate as an independent ...rters of combined U.S. commercial operations; Gene...novation will be enhanced through a diversity of r..., partnerships and other key assets , , -- Transa...
Other Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 2PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 3PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 2Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 3Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 5Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 6Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 7
(Date:12/2/2009)PHILADELPHIA Mexican-American adolescents exposed to cigarette smoking scenes in movies are more likely to pick up the habit themselves, and this may be part of the acculturation process associated w
(Date:12/2/2009)PHILADELPHIA Assurance of a cancer-free status did not prompt people participating in a long-term computerized tomography (CT) lung-cancer screening program to pick up their cigarettes again, researc
(Date:12/2/2009)Recalls of ground beef, peanut butter, and other foods have done more than raise public awareness and concern about food safety. They also are quietly fueling a boom in the market for food testing equ
Breaking Biology News(10 mins):Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 1Ligon Discovery Announces Appointment of Errol B De Souza as Executive Chairman 6480 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 1NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 2NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 6476 3Burnout and mental distress strongly related to errors by US surgeons 61962 1Burnout and mental distress strongly related to errors by US surgeons 61962 2
...National Institutes of Health (NIH) has awarded $4...search projects that could have an extraordinarily...grants, from a new program called EUREKA (for Exce...e Acceleration), targets investigators who are tes...ing major methodological or technical advances. E...
...rs for the detection of diseases including cancer ...ne this week in Cell Research . The findings pave...ic tool. , miRNAs are a class of naturally occurr...th cancer development. Recent studies reporting in...ic cancers were unable to rule out the possibility...
... released outside of their native ranges to contro...found that through complex community interactions ...ence of an introduced fly may exacerbate the effec...The authors report their results in the September ... Spotted knapweed, a flowering plant native to Eu...
Other Biology News:NYU Cancer Institute researcher among first NIH EUREKA award recipients 2Biocontrol insect exacerbates invasive weed 2Biocontrol insect exacerbates invasive weed 3
...Flow Perm/Wash Buffer I can be used in intracellul...ling proteins to permeabilize cells and to serve a...e saponin-mediated cell permeabilization is a reve...in the presence of saponin during intracellular st...
Mouse Anti-Human PREB Polyclonal Antibody, Unconjugated from Abnova Corporation
Mouse Anti-Human ACTN4 Monoclonal Antibody, Unconjugated, Clone 4D10 from Abnova Corporation
...iendly Eppendorf Thermomixer R offers maximum appl...equire shaking, heating, and cooling. Its active h...pplication and temperature control ranges. Five di...4 micro test tubes, are available for: 0.5 ml, 1.5...
Biology Products: